influenza
viru
caus
highmort
diseas
human
effect
therapeut
avail
report
human
monoclon
antibodi
bind
hemagglutinin
ha
protect
infect
bind
ha
subnanomolar
affin
acid
ph
lower
affin
neutral
ph
highresolut
crystal
structur
complex
ha
indic
bind
epitop
may
fulli
expos
upon
phinduc
conform
chang
ha
fulli
protect
mice
lethal
challeng
viru
mechan
like
involv
antibodydepend
cellmedi
cytotox
interestingli
immunogenet
analysi
indic
germlin
antibodi
sequenc
identifi
patient
healthi
adult
newborn
babi
properti
offer
templat
vaccin
immunogen
promis
candid
therapeut
tool
explor
mechan
viru
infect
inhibit
antibodi
like
highli
pathogen
avian
influenza
viru
subtyp
avian
influenza
viru
subtyp
also
continu
seriou
threat
public
health
gao
et
al
may
total
laboratoryconfirm
human
infect
case
report
http
wwwwhointcsrdon
case
mainland
china
viru
also
spread
hong
kong
taiwan
macao
malaysia
canada
lin
et
al
serious
ongo
fifth
epidem
wave
repres
largest
outbreak
sinc
first
appear
laboratoryconfirm
human
infect
much
widespread
geograph
distribut
sinc
octob
current
howev
approv
vaccin
avail
prevent
viral
infect
even
though
vaccin
candid
enter
clinic
trial
tang
et
al
addit
although
sensit
neuraminidas
inhibitor
oseltamivir
tamiflu
zanamivir
relenza
tang
et
al
yen
et
al
data
laboratoryscal
studi
show
treatment
option
possibl
product
resist
strain
may
render
influenza
antivir
drug
ineffect
tang
et
al
yen
et
al
kiso
et
al
find
call
develop
new
effect
therapeut
approach
combat
human
infect
monoclon
antibodi
mab
explor
therapeut
virus
includ
human
immunodefici
zhou
et
al
huang
et
al
huang
et
al
sever
acut
respiratori
syndrom
coronaviru
sarscov
nipah
hendra
virus
zhu
et
al
xu
et
al
geisbert
et
al
influenza
viru
hemagglutinin
ha
trimer
surfac
glycoprotein
primari
target
vaccin
antivir
develop
ha
facilit
viru
entri
bind
sialic
acid
receptor
use
globular
head
region
subunit
undergo
acid
phinduc
conform
chang
result
fusion
viral
cellular
membran
notabl
major
influenza
antibodi
elicit
immun
infect
direct
five
antigen
site
globular
head
design
cb
sa
sb
gerhard
et
al
caton
et
al
zuo
et
al
recent
number
neutral
nonneutr
mab
target
stem
region
identifi
could
mediat
antivir
effect
fcfcg
receptor
interact
antibodydepend
cellmedi
cytotox
adcc
kallewaard
et
al
dilillo
et
al
dunand
et
al
tan
et
al
howev
remain
controversi
whether
adcc
effect
particip
function
antibodi
jegaskanda
et
al
dilillo
et
al
dilillo
et
al
furthermor
epitop
capabl
elicit
protect
adccantibodi
yet
identifi
ye
et
al
studi
aim
develop
influenza
fulli
human
mab
hmab
minim
diverg
germlin
predecessor
recombin
ha
protein
select
antigen
sequenti
pan
larg
naiv
antibodi
librari
construct
blood
healthi
adult
donor
interestingli
one
select
antibodi
design
neutral
viru
tissu
cultur
rather
induc
strong
adcc
activ
highli
effect
viru
infect
mous
model
bound
ha
phdepend
high
affin
uniqu
epitop
distinct
convent
antigen
site
identifi
highresolut
crystal
structur
complex
anoth
uniqu
featur
germlin
sequenc
suggest
vaccin
base
epitop
could
highli
effect
develop
candid
antivir
agent
could
easier
compar
highli
somat
mutat
antibodi
use
peripher
blood
b
cell
healthi
donor
previous
prepar
larg
phagedisplay
antibodi
fab
librari
use
pan
number
viral
cancerrel
target
ying
et
al
ying
et
al
feng
et
al
puligujja
et
al
studi
design
sequenti
pan
strategi
isol
antibodi
antibodi
librari
first
pan
baculovirusexpress
ha
isol
pan
fcfuse
isol
four
round
figur
signific
enrich
observ
fourth
round
pan
figur
panel
antibodi
select
one
antibodi
design
bound
potent
ha
protein
also
reactiv
ha
although
lesser
extent
ha
subtyp
includ
figur
next
analyz
sequenc
use
imgt
tool
determin
closest
vh
vl
germlin
gene
interestingli
found
vh
gene
share
ident
germlin
includ
ident
framework
heavychain
complementaritydetermin
region
hcdr
gene
figur
vl
gene
also
close
germlin
ident
except
point
mutat
lead
chang
met
leu
posit
locat
n
terminu
light
chain
figur
revers
mutat
mutant
effect
antigen
bind
figur
fact
igkv
allel
methionin
posit
allel
etc
leucin
posit
suggest
point
mutat
light
chain
posit
due
allel
polymorph
rather
somat
mutat
notabl
gene
dominantli
use
number
antivir
antibodi
includ
target
influenza
virus
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
among
other
ying
et
al
huang
et
al
pappa
et
al
lingwood
et
al
prabakaran
et
al
investig
immunogenet
characterist
antibodi
analyz
detail
recombin
frequenc
specif
ighd
ighj
gene
use
nextgener
sequenc
data
antibodyom
studi
naiv
immunoglobulin
igm
repertoir
healthi
adult
donor
neonat
igm
repertoir
newborn
babi
analysi
reveal
one
frequent
use
ighv
gene
figur
among
total
sequenc
healthi
adult
igm
repertoir
sequenc
found
display
v
j
recombin
indic
rel
high
frequenc
specif
v
j
recombin
pattern
figur
similar
recombin
frequenc
also
observ
igm
repertoir
newborn
babi
sequenc
v
j
recombin
identifi
sequenc
figur
align
sequenc
sequenc
igm
repertoir
success
identifi
number
clone
share
high
sequenc
similar
figur
remark
sequenc
share
ident
includ
vdj
junction
residu
heavi
chain
found
igm
repertoir
newborn
babi
figur
furthermor
previous
sequenc
antibodi
repertoir
patient
hou
et
al
although
possibl
accur
map
frequenc
v
j
recombin
due
limit
number
b
cell
obtain
patient
still
identifi
number
sequenc
share
signific
degre
similar
figur
next
assess
potenti
compat
vhvl
pair
search
imgt
databas
found
vhvl
pair
also
exist
previous
describ
antibodi
includ
human
antibodi
huang
et
al
antidengu
viru
antibodi
fibriansah
et
al
antibodi
bernasconielia
et
al
indic
immunolog
relev
cognat
vhvl
pair
type
taken
togeth
result
reveal
potenti
elicit
germlin
antibodi
vaccin
highaffin
phsensit
bind
trimer
ha
influenza
ha
exist
homotrim
virion
surfac
mimic
nativ
ha
gener
trimer
ha
fuse
trimer
foldon
c
terminu
ha
interestingli
exhibit
phsensit
bind
ha
bound
trimer
ha
subnanomolar
affin
ph
bind
ph
weaker
k
versu
nm
e
germlineroot
circular
phylogenet
tree
antibodi
sequenc
found
igm
librari
deriv
healthi
human
adult
neonat
patient
sequenc
clone
ident
shown
red
sequenc
id
start
cb
repres
sequenc
deriv
neonat
start
hh
repres
sequenc
deriv
healthi
adult
start
repres
patient
phylogenet
tree
construct
neighborjoin
method
figur
increas
affin
ph
result
increas
onrat
constant
k
versu
decreas
offrat
constant
k
versu
interestingli
bind
affect
chang
ph
bind
affin
nm
similar
trimer
ha
acid
ph
nm
figur
show
bind
ha
figur
result
suggest
recogn
nativ
epitop
could
better
expos
owe
low
phinduc
ha
conform
chang
crystal
structur
fab
complex
map
bind
epitop
determin
crystal
structur
fab
complex
fragment
highresolut
figur
tabl
overal
structur
show
bind
uniqu
epitop
ha
consist
high
bind
affin
interact
surfac
buri
total
area
heavychain
variabl
domain
v
h
lightchain
variabl
domain
v
l
involv
interact
grip
antigen
six
cdr
figur
high
resolut
exact
contact
interfac
determin
without
ambigu
figur
princip
interact
v
h
hydrophob
make
extens
contact
hydrophob
pocket
form
residu
figur
tabl
unlik
v
h
v
l
interact
primarili
electrostat
interact
loop
observ
form
hydrogen
bond
hydrophil
residu
figur
tabl
receptorbind
site
rb
ha
similar
influenza
viru
ha
compos
loop
helic
tharakaraman
et
al
xiong
et
al
evid
epitop
distinct
rb
figur
previous
report
ha
studi
ha
purifi
monom
form
trimer
crystal
structur
yang
et
al
superposit
form
trimer
form
result
ca
rootmeansquar
deviat
indic
bind
induc
signific
conform
chang
interest
note
antibodi
epitop
buri
trimer
structur
figur
acid
ph
ha
undergo
conform
chang
lead
dissoci
top
domain
trimer
spike
improv
access
epitop
explain
mab
immobil
activ
biosensor
analyt
consist
serial
dilut
nm
trimer
ha
ph
ph
b
ph
c
nm
ha
ph
bind
kinet
evalu
use
langmuir
bind
model
fortebio
data
analysi
softwar
differ
bind
affin
trimer
ha
neutral
acid
ph
previou
studi
indic
presenc
five
convent
antigen
site
molecul
includ
sa
sb
cb
extens
character
use
monoclon
polyclon
mous
antibodi
gerhard
et
al
caton
et
al
immunodomin
antigen
region
correspond
four
topograph
distinct
region
found
epitop
distinct
convent
antibodi
epitop
figur
epitop
also
highli
conserv
among
differ
isol
well
influenza
viru
subtyp
indic
recogn
uniqu
epitop
hemagglutin
inhibit
hi
assay
igg
show
weaktomoder
hi
activ
endpoint
mgml
figur
next
measur
neutral
activ
live
virus
interestingli
polyclon
sera
immun
rabbit
sheep
potent
neutral
virus
antibodi
show
neutral
live
virus
figur
confirm
find
assess
neutral
viru
use
imagingbas
immunofluoresc
assay
chai
et
al
viral
replic
quantifi
measur
level
influenza
nucleocapsid
protein
express
shown
figur
posit
control
antibodi
inhibit
viral
replic
approxim
hr
postinfect
neutral
viru
concentr
mgml
taken
togeth
result
indic
effect
neutral
virus
also
monitor
whether
interfer
either
viral
attach
e
b
cell
surfac
receptor
target
cell
membran
fusion
e
f
label
viru
incub
appli
cell
min
examin
viral
attach
membran
fusion
respect
min
postinfect
mpi
monitor
label
virus
red
dot
cell
virus
incub
still
enter
cell
label
virus
neuraminidasetr
control
significantli
decreas
figur
moreov
entryfus
assay
mpi
dioc
signal
detect
posit
control
bafilomycin
antibodytr
group
similar
control
merscov
antibodi
neither
cell
bind
membran
fusion
viru
affect
igg
figur
next
assess
whether
igg
could
elicit
adcc
effect
exhibit
strong
bind
cell
express
ha
visual
confoc
microscopi
figur
adcc
activ
measur
two
assay
dualluciferas
report
genebas
adcc
assay
convent
peripher
blood
mononuclear
cell
pbmc
base
cytotox
assay
potent
human
mab
target
highli
conserv
epitop
ha
stem
dreyfu
et
al
use
posit
control
shown
figur
elicit
robust
adcc
haexpress
cell
wherea
neg
control
antibodi
unrel
antimerscov
antibodi
elicit
low
undetect
adcc
remark
capabl
elicit
evid
higher
adcc
activ
demonstr
potent
mediat
adcc
dreyfu
et
al
cox
et
al
similarli
found
mediat
potent
adcc
effect
concentrationdepend
manner
use
human
pbmc
effector
cell
figur
explor
prophylact
efficaci
balbc
mice
treat
via
intraperiton
rout
two
differ
dose
antibodi
mg
per
mous
antibodi
use
studi
human
backbon
hr
mice
challeng
intranas
ml
lethal
dose
ld
viru
clinic
manifest
weight
loss
mortal
mice
monitor
day
shown
figur
mice
control
group
pb
die
day
viral
challeng
contrast
mg
confer
full
protect
lethal
infect
mice
mg
per
mice
partial
protect
mice
similarli
mice
control
group
gradual
lost
weight
infect
eventu
die
figur
although
mice
receiv
mg
also
show
gradual
weight
loss
infect
bodi
weight
start
recov
day
postinfect
even
increas
studi
end
figur
mice
receiv
mg
group
lost
approxim
bodi
weight
day
start
recov
taken
togeth
result
indic
highli
effect
prophylact
modal
protect
mice
infect
diseas
evalu
therapeut
activ
infect
balbc
mice
infect
ml
lethal
dose
ld
viru
hr
treat
via
intraperiton
rout
mg
shown
figur
treatment
antibodi
mg
abl
protect
mice
legend
next
page
fulli
lethal
caus
infect
challeng
mice
treat
low
dose
mg
infect
mice
surviv
anim
control
group
rapidli
lost
weight
figur
howev
treatment
infect
mice
start
recov
bodi
weight
approxim
day
postinfect
result
demonstr
adccmedi
antibodi
whether
administ
prophylact
therapeut
agent
could
like
neutral
antibodi
decreas
mortal
morbid
mice
infect
explor
lung
patholog
one
mous
randomli
kill
group
day
postinfect
effect
antibodi
treatment
pulmonari
bronchial
patholog
associ
infect
evalu
compar
uninfect
mice
seriou
pulmonari
interstiti
pneumonia
observ
lung
tissu
mice
control
group
figur
larg
amount
exud
sever
edema
infiltr
lymphocyt
cell
also
seen
n
ld
viru
monitor
daili
day
accumul
mortal
weight
loss
b
express
percent
weight
loss
surviv
respect
n
per
group
pb
use
control
group
therapeut
efficaci
studi
mice
treat
ip
antibodi
hr
viral
challeng
ld
viru
monitor
daili
day
accumul
mortal
c
weight
loss
weight
loss
b
repres
mean
chang
bodi
weight
per
group
sd
also
shown
e
evalu
histopatholog
chang
pulmonari
tissu
uninfect
mice
mice
therapeut
prophylact
control
group
black
yellow
blue
arrow
repres
infectioninduc
inflamm
blood
vessel
alveoli
capillari
respect
f
evalu
histopatholog
chang
bronchial
tissu
black
yellow
blue
green
arrow
repres
bronchial
epitheli
cell
bronchial
alveoli
capillari
interstiti
tissu
respect
contrast
mice
receiv
therapi
prophylaxi
high
low
dose
mild
pulmonari
interstiti
pneumonia
alveol
figur
similar
result
found
bronchial
tissu
shown
figur
bronchial
epitheli
show
cytopath
effect
control
group
includ
bronchial
epitheli
cell
degener
necrosi
desquam
contrari
sign
patholog
larg
decreas
mice
administ
figur
viru
infect
human
high
mortal
pose
signific
threat
public
health
reinforc
urgenc
develop
effect
antivir
therapi
infect
therapeut
antibodi
broadli
develop
prevent
viral
infect
licens
antibodi
keller
stiehm
hepat
b
viru
respiratori
syncyti
viru
rabi
viru
varicella
zoster
viru
cytomegaloviru
develop
antibodi
sarscov
merscov
nipah
hendra
virus
zhou
et
al
huang
et
al
huang
et
al
geisbert
et
al
xu
et
al
zhu
et
al
ying
et
al
wang
et
al
notabl
except
isol
mab
infect
vaccin
subject
larg
naiv
antibodi
librarybas
technolog
enabl
rapid
develop
highaffin
hmab
highlight
potenti
use
antibodybas
antivir
emerg
virus
diseas
occur
outbreak
set
instanc
use
larg
naiv
antibodi
librari
success
identifi
three
hmab
merscov
includ
ying
et
al
ying
et
al
among
exhibit
ultrapot
neutral
activ
half
maxim
inhibitori
concentr
ic
mgml
vitro
also
highli
effect
three
differ
anim
model
rabbit
houser
et
al
mous
agraw
et
al
marmoset
van
doremalen
et
al
present
studi
identifi
human
mab
uniqu
properti
make
promis
candid
therapeut
well
templat
vaccin
develop
current
sever
hmab
therapeut
potenti
treat
infect
henri
dunand
et
al
chen
et
al
tharakaraman
et
al
wang
et
al
dunand
et
al
thornburg
et
al
mab
exhibit
compar
activ
mous
model
infect
howev
potenti
develop
depend
respect
properti
factor
difficult
predict
requir
detail
character
number
properti
includ
exampl
propens
aggreg
level
express
gener
germlin
antibodi
better
drugabl
safeti
compar
antibodi
high
somat
mutat
dimitrov
one
exampl
antibodi
hendra
nipah
virus
near
germlin
exhibit
good
drugabl
includ
success
complet
phase
clinic
trial
healthi
volunt
zhu
et
al
zhu
et
al
bossart
et
al
geisbert
et
al
therefor
expect
similarli
good
drugabl
could
develop
use
candid
therapeut
germlin
natur
antibodi
also
impli
similar
antibodi
elicit
rel
fast
low
number
somat
mutat
requir
affin
matur
contrast
antibodi
like
chronic
infect
could
highli
diverg
put
germlin
predecessor
may
requir
extens
complex
affin
matur
pathway
obtain
breadth
potenc
hoot
et
al
jardin
et
al
inde
recent
found
neutral
mab
isol
vaccin
recipi
possess
low
number
somat
mutat
suggest
clone
aros
naiv
b
cell
thornburg
et
al
structur
analysi
suggest
junction
residu
play
import
role
bind
agreement
previou
find
germlinelik
antibodi
achiev
highaffin
bind
antigen
vd
dj
junction
segment
allelicspecif
residu
ying
et
al
solv
crystal
structur
complex
antigen
structur
epitop
known
could
use
templat
vaccin
immunogen
could
specif
elicit
antibodi
approach
use
develop
vaccin
immunogen
virus
includ
merscov
vari
success
jardin
et
al
jardin
et
al
steichen
et
al
bonsignori
et
al
schmidt
et
al
appear
could
use
virus
typic
caus
acut
infect
elicit
antibodi
rel
low
number
mutat
still
capabl
potent
inhibitori
activ
interestingli
show
weaktomoder
hi
activ
exhibit
neutral
activ
live
viru
furthermor
interfer
viral
attach
membran
fusion
indic
imagingbas
immunofluoresc
assay
could
explain
uniqu
epitop
locat
opposit
rb
head
ha
surprisingli
elicit
potent
adcc
stembind
antibodi
contrari
previou
find
antistem
antibodi
antihead
antibodi
abl
mediat
robust
adcc
cox
et
al
dilillo
et
al
recent
propos
optim
antibodymedi
adcc
depend
interact
influenza
ha
sialic
acid
receptor
immun
cell
thu
antihead
antibodi
block
sialic
acid
receptor
interact
ha
inhibit
fcgriiia
activ
adcc
elicit
cox
et
al
regard
like
epitop
mask
even
becam
expos
bind
ha
sialic
acid
receptor
allow
subsequ
bind
elicit
potent
adcc
anoth
interest
featur
ph
depend
bind
trimer
ha
fact
bind
affect
ph
chang
bind
affin
monomer
similar
trimer
ha
acid
ph
suggest
epitop
sensit
conform
chang
ha
head
accord
vitro
assay
bind
appar
interfer
viral
entri
nonetheless
experi
requir
identifi
certainti
whether
better
exposur
epitop
could
induc
bind
ha
sialic
acid
receptor
play
role
elicit
potent
adcc
conclus
identifi
hmab
appear
exhibit
sever
uniqu
featur
could
contribut
use
reagent
explor
mechan
entri
cell
develop
therapeut
vaccin
detail
method
provid
onlin
version
paper
includ
follow
fibriansah
g
tan
jl
smith
sa
de
alwi
r
ng
ts
kostyuchenko
va
jadi
rs
kukkaro
p
de
silva
crow
je
et
al
highli
potent
human
antibodi
neutral
dengu
viru
serotyp
bind
across
three
surfac
protein
nat
commun
gao
r
cao
b
hu
feng
z
wang
hu
w
chen
j
jie
z
qiu
h
xu
k
et
al
human
infect
novel
avianorigin
influenza
viru
n
engl
j
med
geisbert
tw
mire
ce
geisbert
jb
chan
yp
agan
kn
feldmann
f
fenton
ka
zhu
z
dimitrov
ds
scott
dp
et
al
therapeut
treatment
nipah
viru
infect
nonhuman
primat
neutral
human
monoclon
antibodi
sci
transl
med
gerhard
w
yewdel
j
frankel
webster
r
antigen
structur
influenza
viru
haemagglutinin
defin
hybridoma
antibodi
natur
henri
dunand
cj
leon
pe
kaur
k
tan
gs
zheng
ny
andrew
huang
qu
x
huang
salgadoferr
et
al
preexist
human
antibodi
neutral
recent
emerg
influenza
strain
j
clin
invest
inform
request
resourc
reagent
may
direct
fulfil
lead
contact
tianlei
ying
tli
fudaneducn
specificpathogenfre
femal
balbc
mice
week
old
purchas
changzhou
caven
laboratori
anim
ltd
changzhou
china
anim
weigh
g
g
five
mice
hous
one
individu
ventil
cage
mice
bred
hous
biosafeti
control
condit
humid
temperatur
c
anim
studi
review
approv
ethic
committe
school
basic
medic
scienc
fudan
univers
permit
number
group
six
mice
receiv
dose
mg
mg
purifi
antibodi
intraperiton
h
prophylact
group
viru
exposur
h
therapeut
group
viru
exposur
mice
inject
pb
control
group
mice
weigh
day
check
daili
order
monitor
weight
loss
surviv
madindarbi
canin
kidney
mdck
cell
obtain
american
type
cultur
collect
atcc
femal
mdck
femal
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
c
co
atmospher
viru
use
anim
studi
ashanghai
obtain
shanghai
public
health
clinic
center
store
c
laboratori
fudan
univers
similar
sequenc
singl
point
mutat
virus
use
neutral
assay
vaccin
strain
virus
gener
revers
genet
obtain
cdc
viru
titer
express
tissu
cultur
infect
dose
tcid
brief
viru
serial
dilut
dilut
viru
sampl
ad
mdck
cell
plate
incub
c
day
tcid
valu
measur
determin
cpe
calcul
reedmuench
method
viru
use
studi
gener
provid
dr
youngki
choi
chungbuk
nation
univers
republ
korea
anim
studi
review
approv
ethic
committe
school
basic
medic
scienc
fudan
univers
permit
number
larg
phagedisplay
human
antigenbind
fragment
fab
librari
construct
use
pbmc
cdna
healthi
volunt
templat
clone
express
antibodi
gene
repertoir
pan
protocol
essenti
carri
describ
previous
ying
et
al
briefli
one
aliquot
frozen
librari
phage
stock
precipit
polyethylen
glycol
peg
peg
nacl
resuspend
pb
recombin
biotinyl
ha
isol
use
first
pan
antibodi
librari
biotinyl
fcfuse
isol
four
round
immobil
streptavidinco
magnet
bead
invitrogen
phage
particl
use
biopan
phage
librari
preblock
milk
powder
wv
pb
mpb
incub
biotinyl
antigen
mpb
min
incub
streptavidinco
magnet
bead
h
wash
pbst
pb
buffer
supplement
tween
bound
phage
use
infect
midlog
phase
e
coli
bacteria
c
h
bacteria
grown
medium
contain
mgml
ampicillin
wv
glucos
c
rpm
h
cell
infect
helper
phage
thermo
fisher
min
room
temperatur
infect
cell
harvest
resuspend
medium
supplement
mgml
ampicillin
mgml
kanamycin
follow
incub
overnight
c
rpm
phage
precipit
cultur
supernat
resuspend
steril
pb
subsequ
pan
enrich
antigenspecif
phage
round
pan
assess
polyclon
phage
enzymelink
immunosorb
assay
elisa
posit
clone
express
fab
identifi
th
th
round
pan
use
monoclon
phage
elisa
corn
halfarea
plate
sigmaaldrich
coat
viral
ha
ngwell
pb
overnight
c
block
milk
powder
wv
pb
buffer
c
phage
elisa
phage
round
pan
polyclon
phage
elisa
clone
randomli
pick
fourth
fifth
round
pan
monoclon
phage
elisa
incub
immobil
antigen
bound
phage
detect
peroxidas
hrp
polyclon
antibodi
pharmacia
piscataway
nj
solubl
fab
bind
assay
serial
dilut
antibodi
ad
incub
h
c
hrpconjug
mous
antiflag
sigmaaldrich
use
detect
enzymat
activ
measur
subsequ
addit
substrat
abt
signal
read
carri
nm
minimum
independ
experi
perform
fab
express
perform
e
coli
bacteri
cultur
accord
protocol
refer
purifi
ninta
column
ying
et
al
convers
prepar
heavi
light
chain
fab
amplifi
reclon
vector
igg
express
transient
use
express
system
thermo
fisher
accord
manufactur
instruct
purifi
protein
affin
chromatographi
ge
healthcar
protein
dialyz
pb
puriti
estim
sdspage
protein
concentr
measur
spectrophotometr
bind
affin
ha
ha
ha
protein
mab
monitor
bli
use
devic
pall
fortebio
briefli
mab
mgml
buffer
sodium
acet
ph
load
onto
activ
biosensor
satur
typic
incub
serial
dilut
viral
ha
run
buffer
ph
associ
dissoci
measur
c
fit
use
fortebio
data
analysi
softwar
sourc
amplif
antibodi
gene
fragment
cdna
revers
transcript
total
rna
extract
b
lymphocyt
healthi
adult
donor
newborn
babi
describ
previous
ying
et
al
cord
blood
newborn
babi
receiv
ndri
care
taken
contamin
sampl
matern
blood
clone
vh
cdna
carri
accord
method
describ
previous
prabakaran
et
al
nextgener
sequenc
perform
use
illumina
hiseq
platform
accord
manufactur
protocol
imgthigh
vquest
use
sequenc
annot
assign
v
j
gene
result
imgthigh
vquest
analysi
import
postgresql
databas
structur
queri
languag
sql
use
retriev
data
statist
analysi
fab
complex
form
mix
protein
molar
ratio
purifi
sizeexclus
chromatographi
hiload
superdex
column
ge
healthcar
purifi
complex
concentr
mgml
crystal
crystal
grown
reservoir
solut
contain
sodium
fluorid
vv
peg
sit
drop
vapor
diffus
c
data
collect
crystal
soak
reservoir
solut
contain
vv
ethylen
glycol
flashfrozen
liquid
nitrogen
xray
l
diffract
data
collect
c
use
rayonix
detector
beamlin
sercat
advanc
photon
sourc
argonn
nation
laboratori
xray
data
process
use
program
hkl
research
inc
structur
solv
molecular
replac
use
phaser
program
embed
phenix
suit
echol
et
al
ha
pdb
fab
antibodi
pdb
search
model
program
coot
phenixrefin
use
model
build
structur
refin
final
structur
evalu
valid
server
wwpdb
data
collect
structur
statist
summar
tabl
coordin
structur
factor
deposit
protein
data
bank
access
code
pdb
hemagglutin
inhibit
assay
conduct
ha
antigen
hors
red
blood
cell
indic
use
routin
method
describ
previous
hobson
et
al
khurana
et
al
polyclon
sera
rabbit
immun
trimer
domain
use
posit
control
unrel
antitumor
igg
use
neg
control
viral
cytopath
effect
cpe
base
neutral
assay
conduct
determin
neutral
antibodi
titer
mab
live
virus
previous
describ
khurana
et
al
polyclon
sera
rabbit
immun
sheep
immun
use
posit
control
brief
serial
dilut
mab
mix
tcid
incub
c
h
next
viru
mab
mixtur
ad
mdck
cell
plate
medium
replac
fresh
dmem
h
later
viral
cytopath
effect
cpe
observ
daili
record
day
postinfect
neutral
experi
perform
condit
minimum
independ
experi
perform
immunostainingbas
neutral
assay
carri
detect
neutral
activ
mab
live
previous
describ
chai
et
al
briefli
cell
grown
confluent
monolay
black
clear
bottom
plate
greiner
bioon
frickenhausen
germani
c
h
fed
optipro
sfm
gibco
usa
prior
viral
infect
viru
dilut
optipro
sfm
moi
incub
min
c
mgml
differ
mab
mixtur
inocul
cell
h
c
co
incub
infect
arrest
pfa
immunostain
conduct
use
influenza
npspecif
mab
abcam
cambridg
uk
detect
virusinfect
cell
confoc
imag
acquir
opera
high
content
screen
system
perkin
elmer
shelton
ct
magnif
imag
analysi
perform
use
inhous
imagemin
softwar
cellbas
bind
assay
cell
transfect
sinobiolog
inc
beij
china
code
fulllength
ha
ctermin
gfp
flag
use
pei
method
accord
manufactur
protocol
h
cell
fix
pfa
block
stain
nm
unrel
antihbv
human
monoclon
antibodi
h
wash
cell
incub
alexa
fluor
conjug
goat
antihuman
igg
thermo
fisher
wash
sampl
mount
confoc
imag
record
leica
confoc
microscop
process
la
af
lite
softwar
entri
assay
perform
previous
describ
banerje
et
al
briefli
cell
grown
black
clear
plate
c
h
viru
label
lipophil
fluoresc
dye
spdioc
sakai
et
al
monitor
cell
bind
membran
fusion
label
viru
moi
incub
mgml
mab
c
inocul
cell
h
c
unbound
virion
remov
wash
three
time
cold
dpb
cell
refe
optipro
sfm
incub
c
cell
fix
pfa
contain
hoechst
mpi
cell
bind
mpi
membran
fusion
respect
neuraminidas
na
use
posit
control
remov
sialic
acid
residu
cell
block
attach
virus
bafilomycin
use
posit
control
inhibit
endosom
acidif
membran
fusion
assay
cell
observ
operetta
highcont
imag
system
perkin
elmer
magnif
minimum
independ
experi
perform
dualluciferas
report
genebas
adcc
assay
perform
use
adcc
report
bioassay
kit
promega
accord
manufactur
instruct
brief
cell
express
ha
cellswel
ml
target
cell
seed
well
flatbottom
cultur
plate
measur
ml
serial
dilut
antibodi
ad
cultur
plate
effector
cell
engin
fcgriiiaexpress
jurkat
lymphocyt
cocultur
antibodytr
target
cell
c
h
luciferas
activ
measur
use
luciferas
assay
regent
luminesc
counter
infinit
pro
sun
et
al
pbmcbase
cytotox
assay
perform
previous
describ
modif
ying
et
al
brief
target
cell
express
ha
cellswel
ml
mix
ml
serial
dilut
antibodi
min
human
pbmc
effector
cell
cellswel
ml
cocultur
antibodytr
target
cell
c
h
adcc
activ
measur
use
cytotoxon
homogen
membran
integr
assay
promega
accord
manufactur
protocol
minimum
independ
experi
perform
one
mous
randomli
select
group
sacrif
day
postchalleng
lung
tissu
challeng
mice
immedi
fix
paraformaldehyd
h
embed
paraffin
tissu
section
mm
thick
stain
haematoxylin
eosin
histopatholog
chang
caus
viru
infect
examin
light
microscop
lung
patholog
analyz
pathologist
blind
experiment
design
previous
describ
chen
et
al
du
et
al
unless
otherwis
state
data
analys
perform
use
graphpad
prism
softwar
result
express
mean
valu
standard
deviat
statist
detail
found
directli
figur
correspond
figur
legend
group
n
femal
week
old
mice
use
experi
investig
blind
histolog
experi
anim
ident
describ
atom
coordin
structur
factor
amplitud
complex
deposit
pdb
access
code
